JP Le Floch, M Lévy, H Mosnier-Pudar, F … - Diabetes Care, 2009 - Am Diabetes Assoc RESULTS—A1C at 4 months was 8.1 ± 0.9 versus 8.0 ± 1.0% with once- and
twice-daily detemir, respectively, with an adjusted between-group difference of
0.12% (95% CI –0.01 to 0.25%), showing noninferiority for once-daily ... Cited by 2 - Related articles - All 3 versions
T Heise, U Eckers, K Kanc, JN Nielsen, L … - Diabetes Technology & Therapeutics, 2008 - liebertonline.com Background: Type 2 diabetes patients on premixed insulin are commonly prescribed
biphasic insulin with low prandial insulin content, such as biphasic insulin
aspart (BIAsp) 30, comprising 30% insulin aspart (IAsp). The new ... Cited by 3 - Related articles - All 3 versions
T Danne, N Datz, L Endahl, H Haahr, C … - Pediatric diabetes, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 3 - Related articles - All 4 versions
- ►diabetesjournals.org ZT Bloomgarden - Diabetes care, 2008 - Am Diabetes Assoc David Goff (Winston-Salem, NC) discussed the ACCORD study design. The goal of
ACCORD was to determine whether cardiovascular disease (CVD) event rates could
be reduced by intensively treating three important risk factors ... Cited by 3 - Related articles - All 6 versions
HH Tsou, CF Hsiao, SC Chow, L Yue, Y Xu, S … - Journal of Biopharmaceutical Statistics, 2007 - ingentaconnect.com In an active controlled noninferiority trial without a placebo arm, one of the
major considerations is the selection of the noninferiority margin. Although the
ICH E10 guideline provides general principles for the selection of ... Cited by 3 - Related articles - BL Direct - All 5 versions
A Wutte, J Plank, M Bodenlenz, C Magnes, W … - Experimental and clinical endocrinology & diabetes: …, 2007 - ncbi.nlm.nih.gov AIMS: This study was conducted to evaluate the dose ratio of insulin detemir and
neutral protamine Hagedorn (NPH) insulin over a range of therapeutically
relevant subcutaneous doses. METHODS: The study was a randomized, ... Cited by 4 - Related articles - BL Direct - All 3 versions
A Dornhorst, HJ Luddeke, C Koenen, M … - Diabetes Obes Metab, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 6 - Related articles - All 4 versions
CF Montanana, CH Herrero, MR Fernandez - Diabetic Medicine, 2008 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 8 - Related articles - All 4 versions
A Philis-Tsimikas - Expert Opin. Pharmacother., 2008 - informahealthcare.com Background: The efficacy and tolerability of insulin detemir (detemir), a
long-acting basal insulin analog, is already well documented for type 1
diabetes. This article reviews new evidence, in particular on the ... Cited by 2 - Related articles - All 7 versions
